BioNTech CEO Ugur Sahin Sells $4.72M in Ordinary Shares Under 10b5-1 Plan
BioNTech SE
Subscribe to track BNTX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Insider Sale Alert: BioNTech SE ($BNTX) Insider: Sahin Ugur (Chief Executive Officer, 10% Owner) Action: Sold 49,000 Ordinary Shares at an avg price of ~$96.37 Total Value: $4,721,975.70 Ownership Post-Transaction: 553,209 direct shares (plus 39,218,111 indirect shares via Medine GmbH) Plan: Rule 10b5-1 trading plan established June 3, 2026
Comprehensive Analysis
Executive Summary
On September 15–16, 2026, Dr. Ugur Sahin, Chief Executive Officer and 10% Owner of BioNTech SE ($BNTX), sold a total of 49,000 ordinary shares across two transactions for gross proceeds of approximately $4.72 million. The transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on June 3, 2026.
Transaction Breakdown
- September 15, 2026: Sold 34,000 ordinary shares at a weighted average price of $96.4893 (~$3.28M).
- September 16, 2026: Sold 15,000 ordinary shares at a weighted average price of $96.0893 (~$1.44M).
- Total Disposed: 49,000 shares for $4,721,975.70.
Ownership Structure Post-Transaction
- Direct Ownership: 553,209 ordinary shares remaining.
- Indirect Ownership: 39,218,111 ordinary shares held through Medine GmbH, where Dr. Sahin is the sole shareholder.
- Impact: The sale represents less than 0.13% of Dr. Sahin's total combined direct and indirect beneficial ownership (39.77M+ shares), indicating routine liquidity management under a structured plan rather than a shift in long-term conviction.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.